Alpenglow Biosciences CEO Nick Reder shared his insights on NIH funding cuts in the Washington Post.
Alpenglow Biosciences is deeply committed to advancing scientific innovation—even in times of fiscal uncertainty. In today’s The Washington Post, our CEO Nicholas Reder shared his thoughtful perspective on the impact funding cuts will have on scientific research support through the National Institutes of Health (NIH) and companies like Alpenglow, which are at the forefront of innovation in biomedical research.
Nick emphasized that robust and consistent support for scientific research is essential not only for groundbreaking discoveries in healthcare and biotechnology but also for ensuring a resilient future for our industry.
Alpenglow Biosciences is at the leading edge of technological innovation, leveraging targeted government funding to bridge the gap between academic breakthroughs and clinical applications. As a growing startup, we prioritize transformative advancements in clinical research, using grants to develop high-risk, high-reward technologies rather than incremental improvements.
We are deeply grateful for the support of multiple grants from the NIH, ARPA-H, and Andy Hill CARE fund that enable us to push the boundaries of what’s possible. Our team remains relentless in our mission to translate cutting-edge science into real-world impact, improving clinical research and patient outcomes.
While policy debates continue, we stand by our commitment to invest in transformative research and collaborate with partners across the scientific community. We believe fostering an environment where innovation thrives is crucial for translating cutting-edge research into life-changing therapies.
We invite you to read Nick’s full perspective in the article below. Together, let’s continue to support and drive forward the science that makes a difference.
https://wapo.st/42RMXrn
